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ABSTRACT: Schizophrenia is a devastating mental illness 
and its etiology is still largely unknown. Several gene mapping 
studies suggest that schizophrenia is a complex disorder, with 
a cumulative impact of variable genetic effects coupled with 
environmental factors. There is evidence that schizophrenia 
could be a neurodegenerative, neuroinflammatory or 
neurodevelopmental disorder. Neuropsychological data indicate 
neurocognitive functions are relatively stable over time after 
illness onset, whereas morphological data indicate a degenerative 
process; potential roles of neuroinflammation in the etiology of 
psychiatric diseases including schizophrenia have also been 
suggested. Recent research indicates genetic overlap between 
schizophrenia and syndromes in which psychopathology 
manifests in childhood and that are often grouped together as 
‘neurodevelopmental disorders’. These findings challenge the 
etiological basis of current diagnostic categories and, together 
with evidence for frequent comorbidity, suggest that we should 
view the functional psychoses as members of a group that result 
in part from a combination of genetic and environmental effects 
on brain development and that are associated with specific and 
general impairments of cognitive function. The objective was to 
perform a systematic literature review of articles on genetics of 
schizophrenia relating to neurodegeneration, neuroinflammation 
and neurodevelopment. After proper filter, we included 40 studies 
and reviewed each finding and its relevance to the hypotheses. 
We can conclude that the evidence points to schizophrenia as a 
neurodevelopmental disease with the direct presence of factors 
related to neuroinflammation and neurodegeneration.
Keywords: Schizophrenia/genetics; Neurodevelopmental disorders/
genetics; Pantothenate kinase-associated neurodegeneration/
genetics; Neurogenetic inflammation/genetics; Genetics.
RESUMO: Esquizofrenia é uma doença mental debilitante e sua 
etiologia é, em sua maior parte, desconhecida. Alguns estudos 
de mapeamento genético sugerem que esquizofrenia é uma 
doença complexa, com impacto acumulativo de fatores genéticos 
variáveis associados a fatores ambientais. Há evidência de que 
a esquizofrenia poderia ser uma doença neurodegenerativa, 
neuroinflamatória ou do neurodesenvolvimento. Dados 
neuropsicológicos indicam que funções cognitivas são 
relativamente estáveis no decorrer do tempo após o início 
da doença, enquanto dados morfológicos indicam processos 
degenerativos; papéis importantes da neuroinflamação na etiologia 
de doenças psiquiátricas, incluindo esquizofrenia, também 
foram sugeridos. Pesquisas recentes indicam sobreposição 
entre esquizofrenia e síndromes cuja fisiopatologia se manifesta 
na infância e são em geral agrupadas como “doenças do 
neurodesenvolvimento”. Estes achados desafiam a base etiológica 
das categorias atuais de diagnóstico e, juntamente com a evidência 
de comorbidade frequente, sugerem que devemos ver as psicoses 
como membros do grupo que resulta em parte da combinação de 
efeitos genéticos e ambientais no desenvolvimento do cérebro e 
que estão associados a prejuízos específicos e gerais da função 
cognitiva. O objetivo foi realizar uma revisão sistemática da 
literatura de trabalhos em genética da esquizofrenia relacionados 
a neurodegeneração, neuroinflamação e neurodesenvolvimento. 
Após buscas específicas, incluímos 40 estudos e revisamos 
cada achado e sua relevância para a hipótese. Nós concluímos 
que a evidência aponta para esquizofrenia como uma doença 
do neurodesenvolvimento com presença direta de fatores 
relacionados a neuroinflamação e neurodegeneração.
Descritores: Esquizofrenia/genética; Transtornos do neurodesen-
volvimento/genética; Neurodegeneração associada a pantotenato-
quinase/genética; Inflamação neurogênica/genética; Genética. 
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INTRODUCTION
Schizophrenia is a common psychiatric disorder, with an estimated prevalence of 
1% in general population and high financial and social 
costs1. The clinical manifestations are divided in positive 
symptoms (hallucination, delusion), negative symptoms 
(social withdrawal, lack of emotion) and cognitive decline 
(memory dysfunction), which are used in the diagnosis of 
schizophrenia, since there is no biomarker for the disease. 
The physiopathology of the disease is unknown, whereas 
several theories have emerged to explain its features: 
neurotransmitters dysfunction (several neurotransmitters 
have been related to schizophrenia, such as dopamine, 
serotonin, GABA and glutamate), neurodevelopment 
abnormalities, neurodegenerative disorder, accelerated 
aging syndrome, neuroinflammation disorder, among 
other described models2,3,4.
The oldest theory was elaborated in 19th- century 
by Kraepelin, who described the disease as “dementia 
praecox”, since young patients progressively, deteriorated 
its cognitive functions while suffering from hallucinations2. 
This description approximates schizophrenia to clinical 
progression of known neurodegenerative processes, such 
as Alzheimer’s disease, creating basis for the development 
of neurodegeneration hypothesis for schizophrenia3. 
Furthermore, some evidence showing enlargement of 
ventricles during disease-years, glutamate excitoxicity, 
oxidative damage and other chemical similarities with 
recognized degenerative processes support this theory. 
However some authors argument, as it occurred with 
Kraepelin afterwards, neurodegeneration model would 
not explain alone all the clinical features of schizophrenia, 
including why a subset of patients improve after 
treatment2,3.
The second theory elaborated was neurodevelopment. 
Despite it had been first proposed in 1873 by Thomas 
Clouston, who described clinical features of the 
“adolescent insanity”, only in mid-1980 it resurged, with 
more robust evidence. Existence of premorbid stage, 
cranial-facial abnormalities, neuroimaging findings in 
first-episode patients, increased risk for the disease when 
obstetric and gestational complications support the theory 
of neural development disorder. This model, however, 
do not explain satisfactorily why the onset is during 
adolescence/young adults period and how a subgroup of 
patients recover after treatment. Detailing the development 
hypothesis was tried to address these problems, such as 
the neonatal ventral hippocampal lesion2, the progressive 
developmental disease3 and the “two-hit” hypothesis4.
Lastly, neuroinflammation model surged more 
recently when, for example, Stevens introduced the 
idea of inflammatory markers in cerebral spinal fluid 
of schizophrenia patients and correlated this with the 
neuropathology5. The most substantial evidence for this 
hypothesis is the findings of statically significant MHC 
classes in three independent Genome Wide Association 
Studies (GWAS)6. Furthermore, a history of autoimmune 
disorders and maternal infections increase the risk of the 
disease; and, although inconsistent, some report activated 
microglia in schizophrenia brain samples6.
Classifying schizophrenia as a neurodevelopment, 
neurodegenerative or neuroinflammation disorder 
would be a step toward more specific therapies, as it 
would facilitate and guide future researches for disease-
modifying agents and symptoms treatment, besides 
improving prevention measures.
METHODS
Systematic reviews in the Medline literature 
database through PubMed for the keywords “schizophrenia 
(MesH Terms) AND neurodevelopment”, “schizophrenia 
(MeSH Terms) AND neurodegeneration” and 
“schizophrenia (MeSH Terms) AND neuroinflammation”.
Firstly, the papers were filtered for language 
(only English), publication date (5 years), species (only 
humans) and article type (excluding reviews). Then, the 
articles were manually selected by title and abstract. 
The papers left were separated into categories: genetics, 
neuroimaging, neurochemistry or clinic. In this review, 
only the works in the category “genetics” were analyzed. 
Lastly, we also excluded papers not available.
RESULTS
During the search, 649 articles were selected for the 
first search step of studies related to neurodegeneration, 
neuroinflammation and neurodegeneration. Only work 
with original genetics of human data remained in the study.
For the neurodegeneration search, 25 articles 
were found and 5 included in the study; for the 
neuroinflammation search, 14 articles were found and 3 
included in the review; for the neurodevelopment search, 
96 articles were found and 32 included (Figure 1).
Despite being found in one of the three searches, 
some papers had overlapping results with other hypothesis. 
Therefore, the findings will be described within each 
hypothesis, but may contain articles found during the 
search of the other model.
In order to facilitate the description of the 
results, we divided the findings according to the type of 
variable tested, which we classified in: Single Nucleotide 
Polymorphism (SNP), mRNA, miRNA, epigenetic and 
others.
The most abundant literature regarding the 
development hypothesis is on single nucleotide 
polymorphisms (SNPs), since we found 21 studies on 
the topic (2 GWAS). In the neurodegeneration search, 
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only 3 studies were found; no study was present in the 
neuroinflammation search.
We found 4 studies from neurodevelopment search, 
3 studies from neuroinflammation search, and 1 study 
from neurodegeneration search regarding mRNA analysis 
in schizophrenia subjects. The common methodology 
(except for two studies) was to analyze mRNA levels in 
patients with schizophrenia of genes already involved in 
one of the three categories (inflammation, development 
and degeneration).
Only two papers studied epigenetic in 
schizophrenia, both found in the neurodevelopment 
search. The studies performed Genome wide DNA 
methylation analysis: the first in discordant twins for 
schizophrenia or bipolar disorder; the second for a limited 
sample of the same diseases.
The only paper on miRNA topic was found in the 
neurodevelopment search, which showed significance for 
one specific miRNA.
Finally we also found 1 study on DNA damage 
during neurodegeneration search; 2 studies on rare variants 
and 2 studies on protein levels in neurodevelopment 
search.
Following, we describe each study included and its 
implications in each model.
Figure 1. Flow diagrama
Neurodegeneration
Schizophrenia is a behavioral disorder, which reveals 
itself in neurocognitive dysfunction. Neuropsychological 
data indicate these functions are relatively stable over 
time after illness onset, whereas morphological data 
indicate a neurodegenerative process. Determining 
whether schizophrenia is a neurodegenerative illness 
with progressive structural changes in the brain after 
presentation of the illness, or a neurodevelopmental 
disorder starting in early life, is of significant importance 
for understanding the pathophysiology.
In one study, authors found that CRP40/mortalin-2 
mRNA was reduced in schizophrenia at first episode and 
in chronic stage, possibly reflecting increased cell stress 
or protein damage7. Heat shock proteins8 are stimulated 
by protein denaturation which can occur in thermal stress, 
oxidative stress, hypoxia, mitochondrial collapse etc. 
Proteotoxic stress is a hallmark of neurodegenerative 
disorders and heat shock proteins are differentially 
regulated in this conditions (some are overexpressed, 
others are underexpressed).
In the same rationale, which alleges cellular 
damage to the cell, one study showed greater DNA damage 
in drug-naïve schizophrenia subjects, when compared to 
control, though the DNA machinery was preserved9.
The hypothesis-free epigenetic experiments 
also support the cellular damage evidence. Authors 
described altered methylation pattern at sites previously 
associated with degeneration disorder, such as Hnrnpa1 
gene (hypomethylated), regulated together with stress-
induced phosphorylation signals. Some mutations have 
already been associated with amyotrophic lateral sclerosis 
and frontotemporal dementia10. GWAS performed in 
association with cognitive measures in schizophrenia 
have not showed any significant SNP for cognitive 
impairment in the disease, but a polygenic score with little 
variance explanation. This method of analysis permits 
the identification of the most statistically relevant SNPs 
for the condition tested, in a large SNP pool (commonly 
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hundreds of thousands SNPs), independently of the 
examiners hypothesis.
Individual SNP studies have implicated Saitohin 
gene11 and ERBB4 pathway12 in the pathogenesis of 
schizophrenia. Saitohin is in linkage disequilibrium 
with tau gene, which codes a well-described protein 
probably involved in Alzheimer’s disease. According to 
Bosia et al.11, it may predict poorer cognitive function in 
the subset of schizophrenia patients with the risk allele. 
ERBB4 pathway, in the other hand, is described in both 
cell death and cell growth metabolism. SNPs in ERBB4 
or NRG1 (Neuregulin-1 – described in more details in 
“Neurodevelopment”) may alter transcription factor bond 
and therefore promote metabolism disturbances, but these 
results do not elucidate whether this is important for 
apoptosis and/or neurogenesis in schizophrenia.
Neuroinflammation
Some evidence suggests the significance of 
neuroinflammation and immunogenetics in schizophrenia. 
Microglia is the major players in innate immunity in the 
CNS. They respond quickly to even minor pathological 
changes in the brain and may contribute directly to 
the neuronal degeneration by producing various pro-
inflammatory cytokines and free radicals. In many 
characteristics, the neuropathology of schizophrenia is 
closely associated with microglial activation13.
Microglial activation (microgliosis) is often 
accompanied by reactive astrocyte activation (astrogliosis), 
and indicates neuroinflammation. However, evidence 
for either microgliosis or astrogliosis in schizophrenia 
is inconsistent. In the study performed by Catts et al.14, 
the subset of schizophrenia patients with increased 
expression of inflammatory markers (such as cytokines) 
showed increased expression of astrogliosis-associated 
mRNA when compared to subset of schizophrenia 
patients with less expression of inflammatory markers, 
but they did not show difference between the overall 
sample of schizophrenia subjects and control. Apparently, 
antipsychotic might reduce gliosis and alter astrocyte 
morphology.
Another gliosis-associated gene, IFITM, mRNA 
was analyzed15. Interferon-induced transmembrane 
protein (IFITM) is a viral restriction factor produced 
by stimulus of cytokines and interferon. Mouse models 
for mild chronic inflammation (for example, NF-kB 
deficiency) have increased levels of IFITM and decreased 
levels of GABA neurons. The study found the same results 
in patients with schizophrenia (increased levels of IFITM 
mRNA in cortical blood vessels and an association with 
GABA neurons decrease). These findings would support 
the theory of neuroinflammation in schizophrenia. 
However, another paper rejected the evidence of 
neuroinflammation16, by comparing microarray data of 
schizophrenia and classical inflammatory conditions 
(such as multiple sclerosis, inflammatory bowel disease 
and dermatomyositis). They concluded that the mRNA 
sets could be separated in two distinct groups: the 
known inflammatory conditions and the neuropsychiatric 
conditions. The possible explanation for the fact that some 
inflammatory molecules are found in the neuropsychiatric 
diseases is that parallel cellular signaling mechanisms 
exist between immune system and nervous system. In 
other words, the same molecules have different roles in 
the systems, for example: complement receptor has a role 
in immune activation as well as in synaptic ‘pruning’17.
Finally, considering the hypothesis of increased 
cytokine secretion in schizophrenia, one study evaluated 
SNPs in IL6 and IL6 receptor genes, but found no 
association with the disease18.
Neurodevelopment
Rosanoff proposed an association of schizophrenia 
with complications of pregnancy and delivery as early as 
1934. According to these, the etiology of schizophrenia 
may involve pathologic processes, caused by both genetic 
and environmental factors, which begin before the brain 
approaches its adult anatomical state in adolescence3.
Several genes in the context of neurodevelopment 
have been studied, as we can see in the Table 1. However, 
only a few SNPs had nominal statistical association with 
the disease, whereas some have been connected with 
neuroimaging differences and cognitive function in both 
control and schizophrenia subjects.
Associations of SNPs with schizophrenia in small-
scale studies were found for SNPs in GSK3B21, BRAP19, 
DLCK120, MYT1L22 and BDNF23, but not for NTNG1. 
Some were validations of previous Genome Wide-
Association studies (GWAS) results.
Moreover, SNPs in genes important for 
neurodevelopment have been correlated with neuroimaging 
variances26-32 and cognitive impairment24,25,33. Specific 
genes had effects in both healthy control and 
schizophrenia subjects; other had effects only in 
schizophrenia individuals or the effects on schizophrenia 
and control were contrary. These findings might not 
indicate an essential role of the genes in the genesis of 
schizophrenia, but may demonstrate the importance of 
neural development variances on the great clinical variety 
of schizophrenia.
Trying to eliminate hypothesis bias, some 
authors performed GWAS. The first concluded that one 
SNP in EIF2AK4 gene was associated with response to 
haloperidol34. We must consider, however, that it did not 
reach GWAS statistical significance and the two samples 
tested showed opposite tendencies. The second GWAS 
performed found no association between any SNP and 
one of the clinical dimensions in schizophrenia (positive 
symptoms, negative symptoms and mood disturbances). 
In this study, only polygenic scores including thousands 
of genes could predict case-control status.
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Table 1. Tested genes and studies’ conclusions
Authors Genes Conclusion
Zhang et al.19 BRAP One SNP was found to be associated with schizophrenia after validation
Håvik et al.20 DCLK1 SNPs found in previous GWASs seems to be associated with schizophrenia as well as with attention deficit disorder, IQ and memory
Li et al.21 GSK3B Three SNPs were associated with schizophrenia and one of them was found to change the transcriptional activity of GSK3B
Li et al.22 MYT1L Difference allelic frequencies were found for one SNP between schizophrenia subjects and control
Zakharyan et al.23 NTNG1 and BDNF
Allelic frequencies of one SNP from BDNF was found to be overrepresented in schizophrenia and associated 
with earlier onset. No differences were found in one NTNG1 SNP
Carmel et al.24 COMT and PRODH
COMT SNP affects executive function in patients with 22q11.2 deletion syndrome. No correlation was found 
for PRODH SNP studied
Lennertz et al.25 SHANK 1 SNP form SHANK1  gene was associated with decreased working memory in schizophrenia and high-risk subjects but not in healthy volunteers
Kido et al.26 YWHAE and DISC1
Significant interaction between SNP from YWHAE and left insula, right putamen and right hippocampus 
volume. No association between SNP from DISC1 and gray matter volume
Takahashi et al.27 DISC1 Association of DISC1 SNP and some neurodevelopmental markers in magnetic resonance image (MRI), such as cavum septic pellucid and orbitofrontal cortex morphology
Takahashi et al.28 YWHAE The orbitofrontal gyrus pattern of schizophrenia subjects was different from control subjects. On the latter group, one SNP was associated with the protective pattern
Nishimura et al.29 EGR3 Genotype for one SNP from ERG3 was associated with smaller oxyHb increase (hypoactivation) in dorsolateral prefrontal cortex on both schizophrenia and control
Tosato et al.30 NRG1 In a sample of individuals with schizophrenia, subjects with one NRG1 SNP had smaller superior temporal gray and white matter volumes
Sim et al.31 ARVCF
Specific haplotypes for SNPs from ARVCF gene were correlated with caudate volume in MRI and 
neurocognitive measurements. The combination of the haplotypes studied also had different behaviors in 
schizophrenia and control (recessive x dominant, respectively)
Wirgenes et al.32 TCF4 TCF4 SNPs were correlated with cognitive dysfunction and decreased cerebellar volume in schizophrenia
Tost et al.33 NRG3 NRG3 SNP risk allele was correlated with increased dorsolateral pre frontal cortex activation (considered as inefficiency) in healthy subjects but the inverse correlation was observed in the schizophrenia group
Maintaining the analysis of large-scale studies, 
another three papers were identified. The first tried to 
correlate sets of SNPs with connectivity within brain 
default mode, which may indicate the resting neuronal 
activity35. This approach differed from GWAS as they used 
multivariate analysis instead of univariate analysis. In 
other words, they used clusters of interacting SNPs instead 
of calculating SNPs risk individually. Another interesting 
difference was the fact they used the brain default mode 
and not the diagnosis itself as the variable in the analysis. 
This means they used an intermediate phenotype, instead 
of the “final” complex phenotype, which might be the 
result of interactions from several other intermediate 
phenotypes. This approach has been considered in the 
literature as an alternative of studying schizophrenia 
itself, because of the complexity and diversity of the 
disease36. The authors found several groups of SNPs 
correlated with each pattern of brain default mode, mainly 
related to neurogenesis, cell adhesion, axon guidance and 
inflammation, among others. The second study intended 
to validate subsets of neural development-related genes 
found in previous GWAS datasets and verified enrichment 
of significative p-values in the neurodevelopment subset37. 
Finally, the third study also collected the evidence 
from previous GWAS and created metabolic pathways 
related to the genes products38. Both neurodevelopment 
and neuroinflammation processes were represented by 
the pathways elaborated, but the authors emphasize the 
possible role of Toll-like receptor family as a connection 
between the various pathways whose disruption may be 
involved in schizophrenia.
Rare variants (less than 5% of frequency in the 
population) may also take part in schizophrenia etiology. 
A genome wide study found increased proportion of rare 
variants in the schizophrenia subjects and analysis was 
enriched for genes expressed in fetal brain39. In another 
study of rare variations, no association was found for 
mutations in PTPRA gene and schizophrenia or autism, 
in spite of some variants found only in the people with 
the diseases may produce damage to protein production. 
PTPRA is believed to be critical to neurodevelopment and 
animal models support association with both autism and 
schizophrenia40.
Existing biomolecular methodologies permit the 
analysis not only of DNA, but also of its products. In 
the papers associated to neurodevelopment, one study 
concluded that GABA related mRNA disturbances in 
schizophrenia seem to not be related with illness chronicity, 
but may be the consequence of blunted or incomplete 
neurodevelopment41. The differences found between 
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schizophrenia subjects and control go in the opposite 
direction of changes in expression during development 
(for example, vGAT, GAD 67 and parvalbumin mRNA 
levels increased during postnatal development, whereas 
they were decreased in schizophrenia subjects compared 
to control). However, since the study used post mortem 
brain sample of chronic patients, it cannot be ruled out 
that GABA related mRNA are disturbed during early 
stages of the disease.
Changes in mRNA Neuregulin 1, which is a 
recognized growth factor, during development have also 
been reported42. The authors describe the mRNA pattern 
from prenatal to old age of different NRG1 subtypes. Some 
SNPs of neuregulin increase the risk of schizophrenia 
in multiple populations and a specific polymorphism at 
NRG1 was associated with altered expression pattern of 
one NRG1 isoform in prenatal and early postnatal periods. 
Therefore, the link between genetic risk and the disease 
might be its interference in neurodevelopment trajectory 
of NRG1 mRNA subtypes. Moreover, diminished NRG1-
induced AKT phosphorylation in lymphoblast was 
associated with smaller hippocampal volume in first-
episode schizophrenia43.
FMR1 gene has also been studied in the context 
of schizophrenia44. This gene encodes for FMRP, which 
is the fragile X mental retardation protein (causative of 
a known inherited mental disability), but FMR1 mRNA 
levels did not differ between schizophrenia and control 
subjects. However, FMRP was decreased in schizophrenia 
and associated with lower IQ and early onset of illness, 
possibly due to abnormal translation or increased 
degradation. Another study replicated the finding of 
reduced FMRP levels and connected this result with 
reduced contrast sensitivity in schizophrenia subjects, 
perhaps by influencing visual pathway development45. 
Thus, FMRP reduced levels might represent the 
neurodevelopment feature of schizophrenia.
Transcriptome made on human induced pluripotent 
cell and neural progenitor cell from one patient with 
schizophrenia showed 228 genes altered only in the neural 
differentiation of the cells from the schizophrenia subject, 
from which ten were related to schizophrenia in previous 
studies and most are important to neurodevelopment 
or plasticity. Additionally, the authors performed a co 
expression analysis of these genes with data of adult brain 
samples of individuals with schizophrenia (compared 
to adult brain samples of control), from which some of 
the “hub genes” found exclusively on the schizophrenia 
group have also been associated with neural development 
disorders (such as CIT and LIN7A)46.
Epigenetic evidence supports the theory of 
neurodevelopment in schizophrenia. Complementary 
results were found in the studies, since the first found 
no difference in global DNA methylation between the 
twins tested47, but disease-associated differences at 
specific CpG islands; the second found a DNA globally 
hypomethylated with regions of hypermethylation48. 
Both performed pathway enrichment analysis, revealing 
pathways related to brain development, axon guidance, 
cell adhesion, metabolism and long-term potentiation.
In these studies, individual genes have also been 
implicated to the disease, such as: ST6GALNAC1 
(hypomethylated) and Npas1 (hypermethylated). 
ST6GALNAC1 is known to be differentially regulated at 
key periods of neurodevelopment; Npas1 has already been 
described as an important mediator of neuron subtypes 
generation49 in pre-natal brain development.
Some precautions must be taken when analyzing 
these results. Both used subjects in treatment and with 
chronic disease, which can affect the methylation pattern. 
Besides, both used small samples, which increase false 
negative results.
miRNA has also been implicated in schizophrenia 
pathology. In one study, the only miRNA that survived 
rigorous statistical analysis for differential expression 
in dorsolateral prefrontal cortex of post mortem brain 
tissue50 was miRNA-132, despite some others had already 
been related to schizophrenia in previous studies51. This 
miRNA is regulated by NMDA signaling and CREB/ERK 
pathway.
In the same study, authors identified negative 
association between miRNA-132 and mRNA from 
Dpyls3 and Dnmt3a, in different times during mouse brain 
development, as well as negative association between 
miRNA-132 and DNMT3A and GATA2 protein levels 
in culture cells. Therefore, Dpyls3, Dnmt3a and Gata2 
are probable targets of miRNA-132, mainly during the 
adolescence period, when miRNA-132 levels increase. 
Described hypofunction of NMDA signaling (mediated 
by glutamate) in the disease and interaction between 
NMDAR and miRNA-132 may explain the abnormal 
miRNA-132 levels in schizophrenia. Indeed, mouse pups 
treated with NMDA antagonist (simulating what might 
happen in the disease) were found to have downregulated 
miRNA-132 and the effect remained in adulthood. This 
pattern may be related to the known NMDA “pruning” 
that occur in normal adolescence but may be deregulated 
in schizophrenia patients52.
Overall, most evidence suggest a main role of 
neurodevelopment in the genesis of schizophrenia, even 
though some participation of genetic factors involved in 
neurodegeneration may also occur.
Limitations
Several limitations of this study and of the data 
interpretation must be considered. First, some of the 
studies used small samples, insufficient to avoid type I 
error. This is a known problem in the field of neurosciences 
and a recent review showed that the median statistical 
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power in neuroscience is 21%, which can produce false 
negatives, results with low predictive positive value, and 
exaggerate the magnitude of the effect53.
Second, schizophrenia is a complex disorder 
and many authors consider it as a syndrome of different 
diseases54. Interestingly, several authors found subsets 
of schizophrenia patients with different biological 
behavior from the other, such as SNPs found only in a 
group of patients with worse performance or determined 
neuroimaging variance. Recently, it was proposed that 
rare variants were present in subgroups of patients and 
determined phenotypic distinct subtypes, for example 
carriers of variants in SLC39A13 showed severe negative 
symptoms and global cognition deficit, suggesting a 
subtype more related to development; carriers of ARMS/
KIDINS220 variants showed cognitive deficits and good 
educational attainment, suggesting degeneration over the 
years55.
The high variability among the patients complicates 
the generalization of genetic markers for the disease. One 
of the possible strategies used to overcome this difficulty 
is the use of endophenotypes, which are intermediate 
and measurable phenotypes filling the gap between the 
clinical manifestations of the psychiatric disorder and 
genetic36. However, this approach was considered only in 
a few articles.
Third, most of the evidence used case-control 
methodologies, but not patient cohorts. The cohort design 
permits to clearly calculate the relative risk of each 
genetic marker and its implications on neuroimaging, 
neurochemistry and cognitive decline described above.
Fourth, large scale studies are still hard to be 
interpreted. In GWASs, for example, despite statistical 
analysis provide a group of associated SNPs, their 
biological manifestations and implications cannot be 
assured and must be confirmed by posterior experiments.
Finally, the methodology used in this systematic 
review might have excluded studies possibly related to 
one of the theories, as only the papers with studies in 
humans were assessed and the quantity of studies found 
in each search was divergent.
DISCUSSION
The most abundant literature found studied 
neurodevelopment-related genes and their role in 
schizophrenia. Only few authors have prospected genetic 
markers for neurodegeneration and neuroinflammation.
Examining the evidence detected, SNPs of genes 
important to neurodevelopment have been associated 
with schizophrenia or neuroimaging/cognitive aspects of 
the disease, including worsening/improvement of these 
aspects in the carriers. In other words, these genes increase 
the risk of the disease or interfere in the prognosis. Even 
hypothesis-free experiments (such as GWAS) have found 
evidence for this.
SNPs are static genetic information and can 
determine or not functional implications (for example if 
there is linkage disequilibrium with a truly risk gene). 
Epigenetic, mRNA and miRNA studies, on the other hand, 
show dynamic information and are closer to cell function at 
determined moment. Hypothesis-free studies on miRNA, 
mRNA and epigenetic showed evidence for disturbance in 
regulation of neurodevelopment-related genes. However, 
one genome-wide methylome also showed differential 
methylation pattern for neurodegeneration-related gene. 
We must consider, however, mRNA of inflammation-
related and degeneration-related genes differentially 
expressed, as analyzed by specific studies.
Interestingly, we observed there was some 
overlap between the genes claimed to be related to 
one of the three theories, such as NRG1. Furthermore, 
many authors did not distinguish one main process, 
but linked, for example, neuroinflammation and 
neurodegeneration as a consequence. In the literature 
of schizophrenia, unifying models have emerged, for 
example “progressive neurodevelopment disease” 
(linking neurodevelopment and neurodegeneration), 
“development neuroinflammation”56 (linking 
inflammation and development), proposing a better 
explanation of clinical features and imaging/chemical 
alterations. In our study, we can consider genetic evidence 
also fits unifying models: altered development signals 
during prenatal phase, inflammation markers at onset and 
gene predisposition to degeneration process, manifesting 
in the chronic phase. We must consider, however, no 
article proved this progression, but only showed indirect 
evidence for each of them and some combinations; 
“inflammation” markers and its role in inflammation or 
synaptic maintenance (as suggested earlier) are still to be 
explained.
CONCLUSION
Considering the papers on physiopathology 
genetic studies of schizophrenia, we can conclude that 
the most substantial evidence support the hypothesis of 
neurodevelopment abnormality. However, when considered 
all the evidence, we must not ignore the possible coexistence 
of both neuroinflammation and neurodegeneration in the 
course of schizophrenia, whose roles are still to be explained 
and linked. In all analyzed studies, the neurodevelopmental 
theory is the most robust on the results and may be 
accompanied by neurodegeneration and neuroinflammation 
way. We can conclude the complexity of schizophrenia 
allows to suggest that the three mechanisms are present, 
with the neurodevelopment as the predominant factor.
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